aTyr Pharma, Inc. (LIFE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1600 |
| Open | 2.3200 |
| Bid | 2.0800 x 1000 |
| Ask | 2.1300 x 1400 |
| Day's Range | 2.0900 - 2.3200 |
| 52 Week Range | 1.8150 - 5.9700 |
| Volume | |
| Avg. Volume | 272,193 |
| Market Cap | 61.21M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7710 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.17 |
- TipRanks
2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon
Penny stocks are controversial, to say the least. When it comes to these under $5 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds. However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in t
- Simply Wall St.
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present f
